CRVO vs. FULC, ABEO, CAPR, ZYBT, ADCT, BNTC, FDMT, INBX, CADL, and LRMR
Should you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include Fulcrum Therapeutics (FULC), Abeona Therapeutics (ABEO), Capricor Therapeutics (CAPR), Zhengye Biotechnology (ZYBT), ADC Therapeutics (ADCT), Benitec Biopharma (BNTC), 4D Molecular Therapeutics (FDMT), Inhibrx Biosciences (INBX), Candel Therapeutics (CADL), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry.
CervoMed vs. Its Competitors
CervoMed (NASDAQ:CRVO) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.
Fulcrum Therapeutics has lower revenue, but higher earnings than CervoMed. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.
Fulcrum Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -290.72%. Fulcrum Therapeutics' return on equity of -31.05% beat CervoMed's return on equity.
In the previous week, Fulcrum Therapeutics had 3 more articles in the media than CervoMed. MarketBeat recorded 6 mentions for Fulcrum Therapeutics and 3 mentions for CervoMed. CervoMed's average media sentiment score of 1.14 beat Fulcrum Therapeutics' score of 1.02 indicating that CervoMed is being referred to more favorably in the media.
CervoMed currently has a consensus target price of $23.71, suggesting a potential upside of 154.45%. Fulcrum Therapeutics has a consensus target price of $7.57, suggesting a potential upside of 13.86%. Given CervoMed's stronger consensus rating and higher probable upside, analysts plainly believe CervoMed is more favorable than Fulcrum Therapeutics.
CervoMed has a beta of -0.79, indicating that its stock price is 179% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500.
25.2% of CervoMed shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 35.4% of CervoMed shares are owned by insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Fulcrum Therapeutics beats CervoMed on 8 of the 15 factors compared between the two stocks.
Get CervoMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CervoMed Competitors List
Related Companies and Tools
This page (NASDAQ:CRVO) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access